Patrick M. Moriarty, MD
Professor, Department of Internal Medicine
Director, Division of Clinical Pharmacology and
Atherosclerosis/ Lipid Apheresis Center
University of Kansas Medical Center
Kansas City, Kansas
Patrick M. Moriarty, MD is a Professor of Medicine at The University of Kansas Medical
Center in Kansas City, Kansas. He is the
Director of Clinical Pharmacology and the Atherosclerosis & Lipoprotein-Apheresis
Center. He earned his Doctorate in Medicine and Surgery at the University of Rome
School of Medicine and Surgery in Italy and completed his residency in Internal Medicine and training in Clinical Pharmacology at the University of Kansas Medical Center.
Dr. Moriarty is a fellow of the American College of Physicians, the American College of
Cardiology, and the National Lipid Association. He is the past president of the International Society for Apheresis and serves as a manuscript reviewer for multiple scientific journals and is the associate editor for The Journal of Clinical Apheresis and Clinical Lipidology. Member of the scientific advisory board for the FH Foundation. Authored or co-authored over 100 articles, abstracts and chapters in peer review journals.
Research activities include atherosclerosis, FH, Lp(a), Lipoprotein-Apheresis, vascular Inflammation, dementia and hemo-rheology. He has participated in numerous clinical trials related to dyslipidemia, Lp(a), obesity, hypertension, and diabetes. His clinical activities involve the treatment and diagnosis of atherosclerosis and cardiovascular disease. The University of Kansas Lipoprotein-Apheresis Center is the largest in North America for the treatment of Familial Hypercholesterolemia and elevated Lp(a).